[Metoprolol, a new effective antimigraine agent]

Presse Med. 1988 Oct 15;17(35):1805-9.
[Article in French]

Abstract

The effectiveness of metoprolol as a prophylactic treatment of migraine was investigated in double-blind comparative trials involving more than 500 patients. In two trials using a slow-release preparation and a dose of 200 mg per day, metoprolol proved significantly better than a placebo and as effective as propranolol 160 mg/day or flunarizine 10 mg/day. At the dose of 100 mg per day metoprolol was significantly more effective than clonidine and clomipramine and not different from a placebo, propranolol 80 mg/day or pizotifen 1.5 mg/day. It is concluded that metoprolol is useful as prophylactic treatment of migraine and ranks among the main drugs used for the same purpose, such as propranolol and pizotifen.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial
  • English Abstract

MeSH terms

  • Clinical Trials as Topic
  • Double-Blind Method
  • Drug Tolerance
  • Humans
  • Metoprolol / adverse effects
  • Metoprolol / therapeutic use*
  • Migraine Disorders / drug therapy*
  • Placebos

Substances

  • Placebos
  • Metoprolol